Late effect of treatment for reducing cardiovascular risk - A hypothesis on cardiometabolic therapeutic memory

Medical Hypotheses

Volumn 73, Issue 1, 2009, Pages 73-79

  Jermendy, György ^a  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; SULFONYLUREA; TRANDOLAPRIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIET THERAPY; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION;

CARDIOTONIC AGENTS; COMPUTER SIMULATION; HEART; HEART DISEASES; HUMANS; MEMORY; MODELS, CARDIOVASCULAR; RISK FACTORS; TIME FACTORS;

EID: 64749099028     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.01.034     Document Type: Article

References (41)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Intensive treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
5. Tuomilehto J., Lindström J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
6. Lindström J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle-intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006) 1673-1679
7. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
8. Li G., Zhang P., Wang J., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371 (2008) 1783-1789
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
10. Bosch J., Lonn E., Pogue J., Arnold M.O., Dagenais G.R., and Yusuf S. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE Study Extension. Circulation 112 (2005) 1339-1346
11. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
12. Buch P., Rasmussen S., Abildstrom S.Z., Køber L., Carlsen J., and Torp-Pedersen C. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 26 (2005) 145-152
13. Jong P., Yusuf S., Rousseau M.F., Ahn S.A., and Bangdiwala S.I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361 (2003) 1843-1848
14. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
15. Pedersen T.R., Wilhelmsen L., Faergeman O., et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 86 (2000) 257-262
16. Strandberg T.E., Pyörälä K., Cook T.J., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
17. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
18. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., and Cobbe S.M. Long-term follow-up of the West of Scotland coronary prevention study. N Engl J Med 357 (2007) 1477-1486
19. The long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
20. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359 (2002) 1379-1387 Erratum:Lancet 2002;360:1430
21. Frick M.H., Elo O., Haapa K., et al. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317 (1987) 1237-1245
22. Tenkanen L., Mänttäri M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
23. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.-.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
24. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
25. Ihnat M.A., Thorpe J.E., Kamat C.D., et al. Reactive oxygen species mediate a cellular "memory" of high glucose stress signalling. Diabetologia 50 (2007) 1523-1531
26. Yamagishi S., Nakamura K., and Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 1 (2005) 93-106
27. Monnier V.M., Sell D.R., and Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 1043 (2005) 567-581
28. Kowluru R.A. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52 (2003) 818-823
29. Kowluru R.A., Chakrabarti S., and Chen S. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NFkappaB) in the retina. Acta Diabetol 41 (2004) 194-199
30. Kowluru R.A., Kanwar M., and Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007 (2007) 21976
31. El-Osta A., Brasacchio D., Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205 (2008) 2683
32. Radford C.R., Schisano B., McTernan P.G., and Ceriello A. The impact of oscillating glucose and the metabolic memory effect on oxidative stress in human endothelial cells. Diabetologia 51 Suppl. 1 (2008) 57Abstract
33. Genuth S., Sun W., Cleary P., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54 (2005) 3103-3111
34. LeRoith D., Fonseca V., and Vinik A. Metabolic memory in diabetes-focus on insulin. Diab Metab Res Rev 21 (2005) 85-90
35. Ihnat M.A., Thorpe J.E., and Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabet Med 24 (2007) 582-586
36. Uusitupa M., Lindi V., Louheranta A., Salopuro T., Lindström J., and Tuomilehto J. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance. 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52 (2003) 2532-2538
37. Elrod J.W., and Lefer D.J. The effects of statins on endothelium, inflammation and cardioprotection. Drug News Perspect 18 (2005) 229-236
38. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
39. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
40. Rydén L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (2007) 88-136
41. Mancia G., de Backer G., Dominiczak A., et al. 2007 guideline for the management of arterial hypertension. The task force of the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187